Advertisement

Search Results

Advertisement



Article Topics

Your search for Christoph Zielinski, MD matches 1 pages

Showing 1 - 1


breast cancer

Overall Survival With Bevacizumab/Capecitabine Noninferior vs Bevacizumab/Paclitaxel in HER2-Negative Breast Cancer

As reported in The Lancet Oncology by Zielinski et al, the final results of the phase III TURANDOT trial showed that overall survival with first-line bevacizumab (Avastin)/capecitabine was noninferior vs bevacizumab/paclitaxel in per-protocol analysis among patients with advanced HER2-negative...

Advertisement

Advertisement



Advertisement